Clinical Trial Update: A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of quizartinib in participants with moderate hepatic impairment has completed, with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Impairment

Drugs mentioned

• Quizartinib (Quizartinib)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Hepatic Impairment, Moderate Impaired Hepatic Function | Phase 1 | Status: COMPLETED | Results posted: 2023-08-01